For reference: 1.7 mg · three weeks · injection-site erythema.
I would like the mechanism, because I want to be able to reason about the cases nobody has written about.
I have tried to reason it out from first principles and got to two contradictory conclusions.
So what is the mechanism, and how well established is it?
three weeks at 1.7 mg is 21 days at one dose level — and the arithmetic the question hides is that it also moves every dose above 1.7 mg back by 21 days. Whether that reduces injection-site erythema depends on which quantity it tracks. A symptom driven by the dose itself is unchanged by waiting: 1.7 mg is 1.7 mg on day 1 and on day 21. A symptom driven by the rate of change has 21 days of no change to settle in, which is the case the hold is actually made for. The distinction is testable on your own record: plot injection-site erythema against days-since-last-increase rather than against dose, and if the peaks line up with the increases the hold is doing something. Escalation schedules are set by a prescriber, and nothing here is medical advice.
Answer first: the titration schedule exists to let tolerance to the gastrointestinal effects develop between steps, and every step in it is a tolerability decision rather than an efficacy one.
For an agent with a one-week half-life, steady state after a dose change is reached in about four to five weeks. Escalating at two weeks means escalating from a position you have not yet reached, and the resulting exposure is higher than the schedule intends.
| Week | Fraction of steady state | Trough as × dose |
|---|---|---|
| 1 | 50 % | 0.50 |
| 2 | 75 % | 0.75 |
| 3 | 88 % | 0.88 |
| 4 | 94 % | 0.94 |
| 5 | 97 % | 0.97 |
| 6 | 98 % | 0.98 |
This is why a four-week step interval is approximately, but not exactly, steady state.
The dose that produces an acceptable result with acceptable tolerability is the endpoint, not the top of the schedule. A substantial fraction of trial participants did well below the maximum.
Titration schedules in the licensed products were designed specifically to manage gastrointestinal tolerability, and that intent is stated in the clinical development literature.
Stepping back is a normal adjustment, not a failure.
edited 18 Mar 2026 by rania_haddad — removed a claim I could not source
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemThe relevant arithmetic is that steady state takes four to five half-lives, so a one-week half-life means a four-week step interval and nothing shorter is informative.
The published semaglutide weight-management schedule steps 0.25, 0.5, 1.0, 1.7 and 2.4 mg at four-week intervals, with 0.25 mg as an initiation step rather than a therapeutic one.
Holding a step for eight weeks instead of four is a legitimate approach with no efficacy cost at the destination, and it is what the trials effectively did for anyone who tolerated poorly.
Faster titration does not reach the destination sooner in any way that matters; it reaches the symptoms sooner.
Slower costs time and nothing else. The ceiling is the same.
The honest answer is that going slower costs time and nothing else, since the exposure ceiling is unchanged.
Escalating while gastrointestinal symptoms are still active is the commonest avoidable error. Tolerance to the previous step has not developed, and the new step lands on top of it.
The relevant detail is that liraglutide titrates weekly rather than four-weekly because its half-life is about thirteen hours, so steady state is reached within days. The interval follows the pharmacokinetics in both cases.
The top of the schedule is not the target. The working dose is.
In practice, this is the single most consequential controllable variable in the whole experience, and people routinely rush it.
The published tirzepatide schedule steps 2.5, 5, 7.5, 10, 12.5 and 15 mg at four-week intervals, with 2.5 mg as the initiation step rather than a therapeutic one.
Hold rather than escalate while symptoms are active. Always.
Answering this needs the agent and the current step, since the schedules differ and the reason they differ is pharmacokinetic.
Titrating downward is available too. Stepping back and holding is a normal adjustment rather than a failure.
Nothing here is medical advice, and research-use compounds are not approved for human use.
Four half-lives between steps, minimum. Work it out for your agent.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.